# MSLT-II: HCP commentary report

> 37 HCP sources screened · 499 verified claims from 36 sources · 12 findings. Updated 2026-10-08.

## Report

- Trial: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection Versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients With Molecular or Histopathological Evidence of Metastases in the Sentinel Node
- NCT ID: NCT00297895
- Registry: https://clinicaltrials.gov/study/NCT00297895
- Sponsor: Saint John's Cancer Institute
- Phase: Not applicable
- Status: Completed
- Indications: Melanoma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-08
- Last checked: 2026-10-08
- Release hash: 7cdbb8b6dae03d3d7e7c995ff85ea5d0cef74562f4404baa4655d89008213300

## Counts

- HCP commentary sources screened: 37
- Sources cited by verified claims: 36
- Verified claims: 499
- Findings: 12
- People found in screened sources: 23
- People identity-verified: 10
- Voices cited: 35

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

MSLT-II centers on whether patients with skin melanoma and a positive sentinel node, but no clinically apparent nodal disease, need further node surgery or can instead undergo ultrasound surveillance. Clinicians discuss survival and regional control, surgical harms, ultrasound expertise and access, CT/PET imaging, adjuvant-treatment evidence and toxicity, transplant-related risks, microscopic deposits and pathology, sentinel-node biopsy’s role, site-specific applicability, patient preferences, and follow-up coordination.

## Open Medical Affairs question

How should Medical Affairs distinguish survival, regional-control, prognostic-information, and morbidity considerations in explanations of surgical de-escalation?

## Findings (titles)

- F1. Avoiding routine completion dissection is the leading reading, but regional control and selective exceptions remain
- F2. Clinical nodal presentation is a critical boundary; imaging can make that boundary less straightforward
- F3. Expert ultrasound and reliable follow-up are conditions of de-escalation, but routine ultrasound alongside CT/PET is contested
- F4. Omitting dissection does not settle the adjuvant-treatment decision, particularly in lower-risk disease
- F5. Transplant-related constraints can produce a different local-treatment choice without proving a dissection benefit
- F6. The completion-dissection result is not read as a reason to abandon sentinel-node biopsy
- F7. Follow-up intensity is pragmatic and risk-sensitive; benefit from earlier systemic treatment remains an open question
- F8. Imaging should change a decision, but baseline timing and postoperative interpretation can also delay care
- F9. Surgical morbidity is a major rationale, but its weight varies by basin, occupation, and patient circumstances
- F10. Head-and-neck and vulvar discussions retain site-specific qualifications rather than a blanket extrapolation
- F11. Small deposits, assay differences, and nonsentinel-node ascertainment complicate risk interpretation
- F12. Implementation includes institutional variation, patient preferences, care ownership, and research infrastructure

## Sample findings

### F3. Expert ultrasound and reliable follow-up are conditions of de-escalation, but routine ultrasound alongside CT/PET is contested

An X thread asked what extra value routine nodal ultrasound offers for sentinel-node-positive patients already receiving CT/PET surveillance.

Source: X thread, 2026-05-27.

### F4. Omitting dissection does not settle the adjuvant-treatment decision, particularly in lower-risk disease

A podcast speaker asked what benefit adjuvant PD-1 therapy offers in stage III melanoma when completion lymph-node dissection has been omitted.

Source: podcast, 2024-12-10.

## Trial aspects

| Aspect | Coverage | Claims | Sources |
| --- | --- | ---: | ---: |
| Completion dissection versus active nodal observation | discussed | 11 | 6 |
| Survival, regional control, and prognostic information | discussed | 9 | 6 |
| Clinical nodal status and response-directed next steps | discussed | 9 | 5 |
| Ultrasound expertise, access, and addition to CT/PET | discussed | 18 | 6 |
| Adjuvant treatment, low-volume disease, and observation choices | discussed | 16 | 7 |
| Transplant and immune-risk constraints | discussed | 9 | 1 |
| Sentinel-node biopsy value and potential replacements | discussed | 22 | 8 |
| Follow-up intensity, timing, and imaging work-up | discussed | 23 | 3 |
| Morbidity, basin-specific surgery, and patient function | discussed | 14 | 9 |
| Head-and-neck and vulvar extrapolation | discussed | 17 | 6 |
| Microscopic burden, pathology, and subgroup interpretation | discussed | 24 | 4 |
| Adoption, patient information preferences, and follow-up ownership | discussed | 32 | 9 |

## Cited sources by channel

- Podcasts: 21
- X threads: 5
- YouTube: 10

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus, give treatment advice.

- Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.
- For 6 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- 2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
- 34 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.
- 3 further source limits are recorded in the machine-readable scope of this record.
- The reviewed material is not representative of all clinicians or all public commentary. Additional potentially relevant recordings were unavailable, and unnamed or differently transcribed trial references may be missing.
- Overlapping releases and podcast/video versions cannot be counted as independent HCP opinions. Source volume does not establish consensus.
- Some passages do not establish who spoke. Their full views remain attributed to unnamed speakers rather than to people listed in programs or participant information.
- Some transcript wording remains uncertain. The low-volume immunotherapy passage does not establish whether treatment is omitted or administered, and the case summary does not clearly establish steroid exposure.
- Reported guideline positions, approval access, study eligibility, endpoint summaries, and practice changes are dated speaker accounts unless expressly identified as verified contextual reporting. Differing retellings have not been silently reconciled.
- Individual cases, small series, retrospective comparisons, biological hypotheses, and speculative subgroup explanations do not establish comparative efficacy or a surgery-benefit subgroup.
- The complete later regional-control publication was unavailable; its supplied context should not be read as a complete assessment of that publication.
- Professional profiles provide context, not passage attribution or additional evidentiary weight. Meredith Gunder, MD's clinical role is unresolved in the supplied professional context.

## Offer

- Size: Standard (36 commentary sources cited)
- Current edition: $1,250. Buy it below; a purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $2,200
- 6 months of weekly updates: $3,100
- 12 months of weekly updates: $4,400
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (10 now), at most $1,250; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/mslt-ii-nct00297895
- Agents: POST https://www.erudio.com/api/orders with {"report": "mslt-ii-nct00297895", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your licence key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Tom and Audun (invoice, PO, questions): https://www.erudio.com/contact?report=mslt-ii-00297895

## Cite

Erudio Health. MSLT-II (NCT00297895): HCP commentary report. Edition 1, v1.0.0. Accepted 2026-10-08. https://www.erudio.com/reports/mslt-ii-nct00297895

## Machine access

- JSON: https://www.erudio.com/reports/mslt-ii-nct00297895.json
- MCP: https://mcp.erudio.com/mcp, tool `get_report_card` with `{"slug": "mslt-ii-00297895"}`